RC

Ritu Chouhan

Active Director Director DIN 09279468
DIN 09279468 First appointment May 2022 Primary industry Healthcare
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2022
Shareholding value •••• Premium profile

About Ritu Chouhan

Data last updated:

Ritu Chouhan is a Director at Inowell Pharma Private Limited (since 2022). The company operates in Healthcare. Inowell Pharma Private Limited reported revenue of ₹1.55 Cr (FY 2025).

DIN 09279468
Primary Designation Director
Industry Healthcare
First Appointment 04 May 2022
Oldest Company Age 8 yrs
Largest company Inowell Pharma Private Limited · ₹1.55 Cr (FY 2025)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Inowell Pharma Private Limited U24239MP2018PTC046364
Director04 May 20222018₹1.55 Cr (FY 2025)Active

Board colleagues of Ritu Chouhan

NameDINCompanyDesignation
Rani Tanwar09279543Inowell Pharma Private LimitedDirector

Directorship timeline

Open interactive timeline →
Inowell Pharma Private Limited
Premium access

Shareholding and investment profile for Ritu Chouhan

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ritu Chouhan

Ritu Chouhan currently holds 1 directorship: Inowell Pharma Private Limited (Director, since 04 May 2022, revenue ₹1.55 Cr (FY 2025)).

Ritu Chouhan was first appointed on 04 May 2022 as Director at Inowell Pharma Private Limited.

The current boards of Ritu Chouhan's companies include Rani Tanwar (Inowell Pharma Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available